StreetAlpha
13F holdings · Q3 2026

Sio Capital Management

New York, NY · files as Sio Capital Management, LLC
Know the moment Sio Capital Management filesYou follow Sio Capital Management An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1482416

Sio Capital Management reported 51 stocks worth $470M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are AVR (8.6%), GMED (7.6%) and GSK (6.9%). Compared with Q2 2026, the fund opened new positions in MRK, REPL and BMRN, added to GMED, GSK and ICLR, trimmed AVR, SNY and ALLO and sold out of COR, TYRA and WAY.

Latest filing: what Sio Capital Management did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
12 new20 added12 trimmed18 sold outBought about $169M · sold about $258M
New 12
See all 12 →
Added 20
See all 20 →
Trimmed 12
  • MMS−$23.8M−62%
  • Cybin Inc−$9.1M−57%
  • ALLO−$6.8M−32%
  • CI−$6.5M−41%
  • VTRS−$3.5M−21%
See all 12 →
Sold out 18
See all 18 →

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$470M−19.5% vs last quarter · $529M including options
Stocks held5112 new · 18 sold out
Top 5 weight33.1%spread out
Turnover91%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
AVR
Anteris Technologies Global
$40.2M8.6%5.2M−367K (−7%)8 of 8
2
GMED
Globus Med Inc
$35.7M7.6%476K+174K (+58%)4 of 8
3
GSK
Gsk PLC ADR F
$32.3M6.9%671K+234K (+54%)4 of 8
4
ICLR
Icon PLC
$24M5.1%141K+53K (+60%)6 of 8
5
SENS
Senseonics Hldgs Inc
$23.3M5.0%2.3M+698K (+44%)4 of 8
6
MRK
Merck & Co Inc
$21.1M4.5%145KNew position4 of 8
7
IDYA
Ideaya Biosciences Inc
$19.2M4.1%500K+20K (+4%)7 of 8
8
SNY
Sanofi
$14.7M3.1%356K−8,018 (−2%)7 of 8
9
ALLO
Allogene Therapeutics Inc
$14.6M3.1%9.1M−4.2M (−32%)2 of 8
10
MMS
Maximus Inc
$14.3M3.0%268K−447K (−62%)8 of 8
🔒 41 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
COR
Cencora Inc
$49.1M174K
TYRA
Tyra Biosciences Inc
$22.2M695K
WAY
Waystar Hldg Corp
$19M926K
ORKA
Oruka Therapeutics Inc
$16.9M177K
CROSS CTRY HEALTHCARE IN
$14.5M1.1M

🔒 Free account: see all 18.

Options

valued at the underlying shares
StockTypeValueSharesChange
MRK
Merck & Co Inc
Put$21.8M150K+150,000
PFE
Pfizer Inc
Put$17.1M600K+600,000
SLS
Sellas Life Sciences Group I
Put$15.1M1.2M0
HAE
Haemonetics Corp Mass
Put$4.7M45K+44,700

Reported value

last 8 quarters
$355MQ4 '24
$330MQ1 '25
$249MQ2 '25
$395MQ3 '25
$603MQ4 '25
$694MQ1 '26
$584MQ2 '26
$470MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Sio Capital Management 13F FAQ

What does Sio Capital Management own?

Sio Capital Management reported 51 stocks worth $470M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are AVR (8.6%), GMED (7.6%) and GSK (6.9%). The table above lists every position in the filing (the top 10 without an account).

What did Sio Capital Management buy and sell in Q3 2026?

Compared with Q2 2026: 12 new positions, 20 added to, 12 trimmed and 18 sold out. New positions include MRK, REPL and BMRN. It sold all of COR, TYRA and WAY.

When will Sio Capital Management file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Sio Capital Management's portfolio worth?

The Q3 2026 filing reports $470M in US stocks ($529M including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.